|Assessment Status||Awaiting HTA submission from Applicant|
|Indication||Is indicated for adult and adolescent patients, 12 years and older, with advanced RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with cabozantinib and/or vandetanib.|
|Rapid review commissioned||08/06/2021|
|Rapid review completed||07/07/2021|
|Rapid review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of selpercatinib compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||22/07/2021|
|Pre-submission consultation with Applicant||08/11/2021|
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.